{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:17:51Z","timestamp":1792034271360,"version":"4.4.0"},"reference-count":102,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T00:00:00Z","timestamp":1639612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Autoimmune encephalitis (AE) is an immune-mediated disease involving the central nervous system, usually caused by antigen-antibody reactions. With the advent of autoantibody-associated diseases, AE has become a hot research frontier in neuroimmunology. The first-line conventional treatments of autoimmune encephalitis consist of steroids, intravenous immunoglobulin (IVIG), plasma exchange (PLEX), and second-line therapy includes rituximab. Despite considerable research and expanding clinical experience, current treatments are still ineffective for a significant number of patients. Although there is no clear consensus, clinical trial evidence limited, and the level of evidence for some of the drugs based on single reports, third-line therapy is a viable alternative for refractory encephalitis patients. With the current rapid research progress, a breakthrough in the treatment of AE is critical. This article aims to review the third-line therapy for refractory AE<\/jats:p>","DOI":"10.3389\/fimmu.2021.790962","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T11:13:22Z","timestamp":1639653202000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":58,"title":["Immunotherapy for Refractory Autoimmune Encephalitis"],"prefix":"10.3389","volume":"12","author":[{"given":"Jiawei","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/91.3.481","article-title":"\u201cLimbic Encephalitis\u201d and Its Association With Carcinoma","volume":"91","author":"Corsellis","year":"1968","journal-title":"Brain"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-009-5431-9","article-title":"Antibodies and Neuronal Autoimmune Disorders of the CNS","volume":"257","author":"Graus","year":"2010","journal-title":"J Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/123.7.1481","article-title":"Paraneoplastic Limbic Encephalitis: Neurological Symptoms, Immunological Findings and Tumour Association in 50 Patients","volume":"123","author":"Gultekin","year":"2000","journal-title":"Brain"},{"key":"B4","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12883-019-1501-5","article-title":"Differences and Diversity of Autoimmune Encephalitis in 77 Cases From a Single Tertiary Care Center","volume":"19","author":"Saraya","year":"2019","journal-title":"BMC Neurol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25655","article-title":"Randomized Placebo-Controlled Trial of Intravenous Immunoglobulin in Autoimmune LGI1\/CASPR2 Epilepsy","volume":"87","author":"Dubey","year":"2020","journal-title":"Ann Neurol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14662","article-title":"A Mouse Model of Seizures in Anti-N-Methyl-D-Aspartate Receptor Encephalitis","volume":"60","author":"Taraschenko","year":"2019","journal-title":"Epilepsia"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0167-10.2010","article-title":"Cellular and Synaptic Mechanisms of Anti-NMDA Receptor Encephalitis","volume":"30","author":"Hughes","year":"2010","journal-title":"J Neurosci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24195","article-title":"Acute Mechanisms Underlying Antibody Effects in Anti-N-Methyl-D-Aspartate Receptor Encephalitis","volume":"76","author":"Moscato","year":"2014","journal-title":"Ann Neurol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1212\/NXI.0000000000000075","article-title":"Complement-Associated Neuronal Loss in a Patient With CASPR2 Antibody-Associated Encephalitis","volume":"2","author":"K\u00f6rtvelyessy","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and Prognostic Factors for Long-Term Outcome in Patients With Anti-NMDA Receptor Encephalitis: An Observational Cohort Study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S1474-4422(10)70253-2","article-title":"Clinical Experience and Laboratory Investigations in Patients With Anti-NMDAR Encephalitis","volume":"10","author":"Dalmau","year":"2011","journal-title":"Lancet Neurol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcr111","article-title":"Autoimmune Encephalitis: A Case Series and Comprehensive Review of the Literature","volume":"104","author":"Wingfield","year":"2011","journal-title":"QJM"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2018.01.004","article-title":"Severe Dysautonomia as a Main Feature of Anti-GAD Encephalitis: Report of a Paediatric Case and Literature Review","volume":"22","author":"Ben Achour","year":"2018","journal-title":"Eur J Paediatr Neurol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-325300","article-title":"Autoimmune Encephalitis: Proposed Best Practice Recommendations for Diagnosis and Acute Management","volume":"92","author":"Abboud","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002635","article-title":"Rituximab Treatment for Autoimmune Limbic Encephalitis in an Institutional Cohort","volume":"86","author":"Lee","year":"2016","journal-title":"Neurology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13291","article-title":"Efficacy and Safety of Rituximab in Autoimmune Encephalitis: A Meta-Analysis","volume":"142","author":"Nepal","year":"2020","journal-title":"Acta Neurol Scand"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e22087","DOI":"10.1097\/MD.0000000000022087","article-title":"Etoposide and Immunotherapy can Improve the Outcome of Severe Anti-GABAB R Encephalitis Presenting With Delta Brush: A Case Report","volume":"99","author":"Wu","year":"2020","journal-title":"Med (Baltimore)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1177\/0883073820923834","article-title":"Autoimmune Encephalitis in Children: A Case Series at a Tertiary Care Center","volume":"35","author":"Rutatangwa","year":"2020","journal-title":"J Child Neurol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s12098-015-1988-8","article-title":"Childhood Anti-NMDA Receptor Encephalitis","volume":"83","author":"Suthar","year":"2016","journal-title":"Indian J Pediatr"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2013.02.008","article-title":"Using Cyclophosphamide in Inflammatory Rheumatic Diseases","volume":"24","author":"Brummaier","year":"2013","journal-title":"Eur J Intern Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-017-8407-1","article-title":"Differences in Treatment of Anti-NMDA Receptor Encephalitis: Results of a Worldwide Survey","volume":"264","author":"Bartolini","year":"2017","journal-title":"J Neurol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.braindev.2018.12.009","article-title":"Clinical Manifestations, Treatment Outcomes, and Prognostic Factors of Pediatric Anti-NMDAR Encephalitis in Tertiary Care Hospitals: A Multicenter Retrospective\/Prospective Cohort Study","volume":"41","author":"Pruetarat","year":"2019","journal-title":"Brain Dev"},{"key":"B23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejpn.2020.10.001","article-title":"Clinical Outcomes of Pediatric Anti-NMDA Receptor Encephalitis","volume":"29","author":"Shim","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2019.12.010","article-title":"Neurodevelopmental Outcomes in Paediatric Immune-Mediated and Autoimmune Epileptic Encephalopathy","volume":"24","author":"Wright","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.clineuro.2018.06.005","article-title":"Breakthrough Treatment With Bortezomib for a Patient With Anti-NMDAR Encephalitis","volume":"172","author":"Schroeder","year":"2018","journal-title":"Clin Neurol Neurosurg"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2019.09.004","article-title":"Bortezomib-Responsive Refractory Anti-N-Methyl-D-Aspartate Receptor Encephalitis","volume":"103","author":"Cordani","year":"2020","journal-title":"Pediatr Neurol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/acn3.557","article-title":"Bortezomib Treatment for Severe Refractory Anti-NMDA Receptor Encephalitis","volume":"5","author":"Shin","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2017.08.011","article-title":"Successful Combined Targeting of B- and Plasma Cells in Treatment Refractory Anti-NMDAR Encephalitis","volume":"312","author":"Sveinsson","year":"2017","journal-title":"J Neuroimmunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13759","article-title":"Plasma Cell Depletion With Bortezomib in the Treatment of Refractory N-Methyl-D-Aspartate (NMDA) Receptor Antibody Encephalitis. Rational Developments in Neuroimmunological Treatment","volume":"25","author":"Keddie","year":"2018","journal-title":"Eur J Neurol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5697670","article-title":"Efficacy of Tocilizumab in Limbic Encephalitis With Anti-CASPR2 Antibodies","volume":"2020","author":"Benucci","year":"2020","journal-title":"Case Rep Neurol Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.pediatrneurol.2018.07.016","article-title":"Tocilizumab in Refractory Autoimmune Encephalitis: A Series of Pediatric Cases","volume":"86","author":"Randell","year":"2018","journal-title":"Pediatr Neurol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebr.2020.100396","article-title":"Super Refractory Status Epilepticus Secondary to Anti-GAD Antibody Encephalitis Successfully Treated With Aggressive Immunotherapy","volume":"14","author":"Jaafar","year":"2020","journal-title":"Epilepsy Behav Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-016-0442-6","article-title":"Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study","volume":"13","author":"Lee","year":"2016","journal-title":"Neurotherapeutics"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-020-00921-7","article-title":"Teratoma Removal, Steroid, IVIG, Rituximab and Tocilizumab (T-SIRT) in Anti-NMDAR Encephalitis","volume":"18","author":"Lee","year":"2021","journal-title":"Neurotherapeutics"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09585-6","article-title":"Daratumumab Treatment for Therapy-Refractory Anti-CASPR2 Encephalitis","volume":"267","author":"Scheibe","year":"2020","journal-title":"J Neurol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.602102","article-title":"Case Report: Daratumumab in a Patient With Severe Refractory Anti-NMDA Receptor Encephalitis","volume":"11","author":"Ratuszny","year":"2020","journal-title":"Front Neurol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2016.09.001","article-title":"New Feasible Treatment for Refractory Autoimmune Encephalitis: Low-Dose Interleukin-2","volume":"299","author":"Lim","year":"2016","journal-title":"J Neuroimmunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou126","article-title":"A Prospective Open-Label Study of Sirolimus for the Treatment of Anti-Hu Associated Paraneoplastic Neurological Syndromes","volume":"17","author":"de Jongste","year":"2015","journal-title":"Neuro Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2016.09.016","article-title":"Extra-Central Nervous System Target for Assessment and Treatment in Refractory Anti-N-Methyl-D-Aspartate Receptor Encephalitis","volume":"37","author":"Nauen","year":"2017","journal-title":"J Crit Care"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318228c136","article-title":"Analysis of Complement and Plasma Cells in the Brain of Patients With Anti-NMDAR Encephalitis","volume":"77","author":"Martinez-Hernandez","year":"2011","journal-title":"Neurology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/bjh.15806","article-title":"Daratumumab, Bortezomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed and Relapsed Multiple Myeloma: LYRA Study","volume":"185","author":"Yimer","year":"2019","journal-title":"Br J Haematol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2012.04.010","article-title":"Bortezomib Combination Therapy in Multiple Myeloma","volume":"49","author":"Kapoor","year":"2012","journal-title":"Semin Hematol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e492","DOI":"10.1097\/TXD.0000000000000931","article-title":"Bortezomib: A New Promising Therapy for Early Antibody-Mediated Rejection After Liver Transplantation","volume":"5","author":"Chedid","year":"2019","journal-title":"Transplant Direct"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.14420","article-title":"Bortezomib Attenuates Renal Interstitial Fibrosis in Kidney Transplantation via Regulating the EMT Induced by TNF-\u03b1-Smurf1-Akt-mTOR-P70S6K Pathway","volume":"23","author":"Zhou","year":"2019","journal-title":"J Cell Mol Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000517","article-title":"Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura","volume":"25","author":"Beckman","year":"2018","journal-title":"Am J Ther"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016001412","article-title":"Bortezomib-Based Antibody Depletion for Refractory Autoimmune Hematological Diseases","volume":"1","author":"Ratnasingam","year":"2016","journal-title":"Blood Adv"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e0124792","DOI":"10.1371\/journal.pone.0124792","article-title":"The Ubiquitin Proteasome System Plays a Role in Venezuelan Equine Encephalitis Virus Infection","volume":"10","author":"Amaya","year":"2015","journal-title":"PloS One"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.neures.2007.01.006","article-title":"Proteasomal Inhibition in Intracerebral Hemorrhage: Neuroprotective and Anti-Inflammatory Effects of Bortezomib","volume":"58","author":"Sinn","year":"2007","journal-title":"Neurosci Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"bcr0320114028","DOI":"10.1136\/bcr.03.2011.4028","article-title":"Breathless on Bortezomib","volume":"2011","author":"O\u2019Riordan","year":"2011","journal-title":"BMJ Case Rep"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003536","article-title":"Bortezomib for Treatment of Therapy-Refractory Anti-NMDA Receptor Encephalitis","volume":"88","author":"Scheibe","year":"2017","journal-title":"Neurology"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-13-155","article-title":"Bortezomib Treatment Causes Long-Term Testicular Dysfunction in Young Male Mice","volume":"13","author":"Hou","year":"2014","journal-title":"Mol Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2013.09.004","article-title":"Targeting Interleukin-6 in Inflammatory Autoimmune Diseases and Cancers","volume":"141","author":"Yao","year":"2014","journal-title":"Pharmacol Ther"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2005.05.010","article-title":"Tocilizumab Inhibits Signal Transduction Mediated by Both mIL-6R and sIL-6R, But Not by the Receptors of Other Members of IL-6 Cytokine Family","volume":"5","author":"Mihara","year":"2005","journal-title":"Int Immunopharmacol"},{"key":"B54","article-title":"Reshaping a Human Antibody to Inhibit the Interleukin 6-Dependent Tumor Cell Growth","volume":"53","author":"Sato","year":"1993","journal-title":"Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000317","article-title":"Efficacy of the Anti-IL-6 Receptor Antibody Tocilizumab in Neuromyelitis Optica: A Pilot Study","volume":"82","author":"Araki","year":"2014","journal-title":"Neurology"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101460","article-title":"Efficacy of Tocilizumab for Fulminant Multiple Sclerosis With a Tumefactive Cervical Lesion: A 12-Year-Old Boy","volume":"37","author":"Hoshino","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2018.01.002","article-title":"Report of Two Cases of Tocilizumab Induced Recurrent Meningitis or Meningoencephalitis","volume":"85","author":"Richeb\u00e9","year":"2018","journal-title":"Joint Bone Spine"},{"key":"B58","doi-asserted-by":"publisher","first-page":"bcr","DOI":"10.1136\/bcr-2018-227296","article-title":"Pseudomonas Meningoencephalitis Masquerading as a Stroke in a Patient on Tocilizumab","volume":"12","author":"Williams","year":"2019","journal-title":"BMJ Case Rep"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.48.1926","article-title":"Leukoencephalopathy With Cognitive Impairment Following Tocilizumab for the Treatment of Rheumatoid Arthritis (RA)","volume":"48","author":"Kobayashi","year":"2009","journal-title":"Intern Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.53.0615","article-title":"Multifocal Encephalopathy and Autoimmune-Mediated Limbic Encephalitis Following Tocilizumab Therapy","volume":"53","author":"Yamaguchi","year":"2014","journal-title":"Intern Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32065","article-title":"Daratumumab in Multiple Myeloma","volume":"125","author":"Nooka","year":"2019","journal-title":"Cancer"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16154","article-title":"Will Daratumumab be the Next Game Changer in Early Thymic Precursor-Acute Lymphoblastic Leukaemia","volume":"187","author":"Mirgh","year":"2019","journal-title":"Br J Haematol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/hon.2677","article-title":"Daratumumab for Relapsed or Refractory AL Amyloidosis With High Plasma Cell Burden","volume":"37","author":"Schwotzer","year":"2019","journal-title":"Hematol Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.214635","article-title":"Daratumumab for Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm. A Single-Case Report","volume":"104","author":"Iversen","year":"2019","journal-title":"Haematologica"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25515","article-title":"Refractory Postallogeneic Stem Cell Transplant Pure Red Cell Aplasia in Remission After Treatment With Daratumumab","volume":"94","author":"Bathini","year":"2019","journal-title":"Am J Hematol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1159\/000503951","article-title":"Daratumumab for Treatment of Antibody-Mediated Rejection After ABO-Incompatible Kidney Transplantation","volume":"9","author":"Spica","year":"2019","journal-title":"Case Rep Nephrol Dial"},{"key":"B67","doi-asserted-by":"publisher","first-page":"e28010","DOI":"10.1002\/pbc.28010","article-title":"Successful Treatment With Daratumumab for Post-HSCT Refractory Hemolytic Anemia","volume":"67","author":"Even-Or","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16171","article-title":"Post-Allogeneic Transplant Evans Syndrome Successfully Treated With Daratumumab","volume":"187","author":"Blennerhassett","year":"2019","journal-title":"Br J Haematol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03877-7","article-title":"Daratumumab-Associated Hemophagocytic Lymphohistiocytosis","volume":"99","author":"Woods","year":"2020","journal-title":"Ann Hematol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102390","article-title":"JAK Inhibitors for the Treatment of Autoimmune and Inflammatory Diseases","volume":"18","author":"Jamilloux","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B71","article-title":"Bethesda. Tofacitinib. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases","year":"2020"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s40265-017-0835-9","article-title":"Tofacitinib: A Review in Rheumatoid Arthritis","volume":"77","author":"Dhillon","year":"2017","journal-title":"Drugs"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01585-7","article-title":"Efficacy of Tofacitinib in the Treatment of Psoriatic Arthritis: A Systematic Review","volume":"38","author":"Gratac\u00f3s Masmitj\u00e0","year":"2021","journal-title":"Adv Ther"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastrohep.2019.03.002","article-title":"Efficacy of Tofacitinib Treatment in Ulcerative Colitis","volume":"42","author":"Pan\u00e9s","year":"2019","journal-title":"Gastroenterol Hepatol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.00963","article-title":"The JAK\/STAT Signaling Pathway","volume":"117","author":"Rawlings","year":"2004","journal-title":"J Cell Sci"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/5021537","article-title":"Tolerogenic Dendritic Cells Generated With Tofacitinib Ameliorate Experimental Autoimmune Encephalomyelitis Through Modulation of Th17\/Treg Balance","volume":"2016","author":"Zhou","year":"2016","journal-title":"J Immunol Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2011.12.156","article-title":"Low Dose CP-690,550 (Tofacitinib), a Pan-JAK Inhibitor, Accelerates the Onset of Experimental Autoimmune Encephalomyelitis by Potentiating Th17 Differentiation","volume":"418","author":"Yoshida","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102568","article-title":"CNS Demyelination During Tofacitinib Therapy: First Report","volume":"46","author":"Massoud","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2015.06.060","article-title":"Aggression Behaviour Induced by Oral Administration of the Janus-Kinase Inhibitor Tofacitinib, But Not Oclacitinib, Under Stressful Conditions","volume":"764","author":"Fukuyama","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16848","article-title":"Tofacitinib Treatment for Refractory Autoimmune Encephalitis","volume":"62","author":"Jang","year":"2021","journal-title":"Epilepsia"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1126\/science.181845","article-title":"Selective In Vitro Growth of T Lymphocytes From Normal Human Bone Marrows","volume":"193","author":"Morgan","year":"1976","journal-title":"Science"},{"key":"B82","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11926-016-0617-5","article-title":"Low-Dose IL-2 in the Treatment of Lupus","volume":"18","author":"Mizui","year":"2016","journal-title":"Curr Rheumatol Rep"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T Cells and Immune Tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4148","article-title":"Low-Dose Interleukin-2 Treatment Selectively Modulates CD4(+) T Cell Subsets in Patients With Systemic Lupus Erythematosus","volume":"22","author":"He","year":"2016","journal-title":"Nat Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701010","article-title":"Successful Treatment of Progressive Multifocal Leukoencephalopathy With Low-Dose Interleukin-2","volume":"20","author":"Przepiorka","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000575","article-title":"Low-Dose Interleukin-2 Therapy for the Treatment of Systemic Lupus Erythematosus","volume":"31","author":"Humrich","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2010.09.002","article-title":"The Mammalian Target of Rapamycin: Linking T Cell Differentiation, Function, and Metabolism","volume":"33","author":"Powell","year":"2010","journal-title":"Immunity"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2015.09.007","article-title":"Valacyclovir Combined With Artesunate or Rapamycin Improves the Outcome of Herpes Simplex Virus Encephalitis in Mice Compared to Antiviral Therapy Alone","volume":"123","author":"Canivet","year":"2015","journal-title":"Antiviral Res"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201600495R","article-title":"Mtorc1 Pathway Disruption Ameliorates Brain Inflammation Following Stroke via a Shift in Microglia Phenotype From M1 Type to M2 Type","volume":"30","author":"Li","year":"2016","journal-title":"FASEB J"},{"key":"B90","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A Clinical Approach to Diagnosis of Autoimmune Encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2017.10.033","article-title":"Pre- and Long-Term Postoperative Courses of Hippocampus-Associated Memory Impairment in Epilepsy Patients With Antibody-Associated Limbic Encephalitis and Selective Amygdalohippocampectomy","volume":"79","author":"Hansen","year":"2018","journal-title":"Epilepsy Behav"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25216","article-title":"Genetic Predisposition in Anti-LGI1 and Anti-NMDA Receptor Encephalitis","volume":"83","author":"Mueller","year":"2018","journal-title":"Ann Neurol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa250","article-title":"Autoimmune Encephalitis Mediated by B-Cell Response Against N-Methyl-D-Aspartate Receptor","volume":"143","author":"Wagnon","year":"2020","journal-title":"Brain"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2015.00167","article-title":"Treating a GAD65 Antibody-Associated Limbic Encephalitis With Basiliximab: A Case Study","volume":"6","author":"Widman","year":"2015","journal-title":"Front Neurol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.107016","article-title":"CD19+ B-Cells in Autoantibody-Negative Limbic Encephalitis","volume":"106","author":"Hansen","year":"2020","journal-title":"Epilepsy Behav"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3390\/jcm5120107","article-title":"Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights From Preclinical Studies","volume":"5","author":"Chen","year":"2016","journal-title":"J Clin Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00905","article-title":"Higher CSF Levels of NLRP3 Inflammasome Is Associated With Poor Prognosis of Anti-N-Methyl-D-Aspartate Receptor Encephalitis","volume":"10","author":"Peng","year":"2019","journal-title":"Front Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12850","article-title":"The HMGB1 is Increased in CSF of Patients With an Anti-NMDAR Encephalitis","volume":"137","author":"Ai","year":"2018","journal-title":"Acta Neurol Scand"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1093\/abbs\/gmy137","article-title":"Th17 Cells Were Recruited and Accumulated in the Cerebrospinal Fluid and Correlated With the Poor Prognosis of Anti-NMDAR Encephalitis","volume":"50","author":"Zeng","year":"2018","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1159\/000472147","article-title":"Chronic Autoimmune Meningoencephalitis and Periodic Fever Syndrome Treated With Anakinra","volume":"9","author":"Novroski","year":"2017","journal-title":"Case Rep Neurol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09988-w","article-title":"Refractory Anti-NMDAR Encephalitis Successfully Treated With Bortezomib and Associated Movements Disorders Controlled With Tramadol: A Case Report With Literature Review","volume":"267","author":"Lazzarin","year":"2020","journal-title":"J Neurol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"e1052","DOI":"10.1212\/NXI.0000000000001052","article-title":"International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis","volume":"8","author":"Nosadini","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.790962\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T11:13:26Z","timestamp":1639653206000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.790962\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,16]]},"references-count":102,"alternative-id":["10.3389\/fimmu.2021.790962"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.790962","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,16]]},"article-number":"790962"}}